Time-to-hepatitis C treatment initiation among people who inject drugs in Melbourne, Australia.
Aung PTZ, Spelman T, Wilkinson AL, Dietze PM, Stoové MA, Hellard ME
Hepatitis C Injecting Drug Use
Current epidemiology and clinical features of Cryptococcus infection in patients without HIV infection: a multicentre study in 46 hospitals from Australia and New Zealand.
Coussement J, Heath CH, Roberts MB, Lane RJ, Spelman T, Smibert OC, Longhitano A, Morrissey O, Nield B, Tripathy M, Davis JS, Kennedy KJ, Lynar SA, Crawford LC, Crawford SJ, Smith BJ, Gador-Whyte AP, Haywood R, Mahony AA, Howard JC, Walls GB, O'Kane GM, Broom MT, Keighley CL, Bupha-Intr O, Cooley L, O'Hern JA, Jackson JD, Morris AJ, Bartolo C, Tramontana AR, Grimwade KC, Au Yeung V, Chean R, Woolnough E, Teh BW, Chen SC, Slavin MA; Australian and New Zealand study group for cryptococcosis in patients without HIV infection.
Validation of a novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study.
Howell J, Van H, Pham MD, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan GW, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson A, Drummer HE, Anderson D
Hepatitis B Hepatitis C
Oncologic outcomes in myxofibrosarcomas: the role of a multidisciplinary approach and surgical resection margins.
Rhee I, Spazzoli B, Stevens J, Hansa A, Spelman T, Pang G, Guiney M, Powell G, Choong P, Di Bella C
Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019.
van Santen DK, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, Smit C, Rauch A, Braun DL, Jarrin I, Berenguer J, Lazarus JV, Lacombe K, Requena MB, Wittkop L, Leleux O, Salmon D, Bonnet F, Matthews G, Doyle JS, Spelman T, Klein MB, Prins M, Asselin J, Stoové MA, Hellard M, InCHEHC study group
Individualized Risk Prediction for Improved Chronic Wound Management.
Veličković VM, Spelman T, Clark M, Probst S, Armstrong DG, Steyerberg E